Kazakhstan
Tuberculosis profile
| High MDR-TB burden |
Population  2012 16 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.3 (1–1.5) 7.8 (6.3–9.3)
Mortality (HIV+TB only) 0.068 (0.055–0.088) 0.42 (0.34–0.54)
Prevalence  (includes HIV+TB) 31 (12–57) 189 (77–350)
Incidence  (includes HIV+TB) 22 (19–26) 137 (116–160)
Incidence (HIV+TB only) 0.26 (0.22–0.31) 1.6 (1.4–1.9)
Case detection, all forms (%) 81 (69–96)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 3 884 (28) Relapse 4 377 (55)
Smear-negative 7 676 (56) Treatment after failure 449 (6)
Smear-unknown / not done 216 (2) Treatment after default 444 (6)
Extrapulmonary 1 844 (14) Other 2 624 (33)
Other 9 (<1)      
Total new 13 629   Total retreatment 7 894  
           
Other (history unknown) 0        
Total new and relapse 18 006   Total cases notified 21 523  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.7 1.2 1.1
Age < 15 25 243 308
Laboratories 2012
Smear (per 100 000 population) 2.9
Culture (per 5 million population) 6.8
Drug susceptibility testing (per 5 million population) 6.8
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 61   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 84  
Retreatment 36  
TB/HIV 2012 Number (%)
TB patients with known HIV status 21 184 (98)
HIV-positive TB patients 441 (2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 71 (16)
HIV-positive TB patients on antiretroviral therapy (ART) 256 (58)
HIV-positive people screened for TB 9 394  
HIV-positive people provided with IPT 862  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 23 (22–24) 55 (54–56)
MDR-TB cases among notified pulmonary
TB cases
2 700 (2 600–2 800) 4 300 (4 300–4 400)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 8 154 (139%) 10 443 (132%) 18 597
Laboratory-confirmed MDR-TB cases 1 864 5 744 7 608
Patients started on MDR-TB treatment     7 213
Financing TB control 2013
National TB programme budget (US$ millions) 242
% Funded domestically 96%
% Funded internationally 4%
% Unfunded <1%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-20 Data: www.who.int/tb/data